LabGenius Therapeutics and LG Chem Enter a Research Collaboration, Option and License Agreement to Develop an AI/ML-Designed Tumour-Targeting Antibody
LONDON, United Kingdom — LabGenius Therapeutics (“LabGenius”), a drug discovery company combining machine learning (ML) and high-throughput experimentation to optimise therapeutic antibodies, today announced a multi-year research collaboration, option and licensing agreement with LG Chem. The collaboration aims to identify next-generation multispecific antibodies designed to overcome the key limitations of existing immunotherapies, including on-target, off-tumor toxicities. Together, the companies will aim to develop a novel, tumor-selective therapeutic targeting a solid tumor antigen expressed across multiple difficult-to-treat cancer types.
“Partnering with LG Chem represents a very important moment for LabGenius and provides further validation of our platform’s ability to design highly optimized multispecific antibodies,” said Dr. James Field, CEO of LabGenius. “We welcome this opportunity to leverage our proprietary discovery capabilities to advance the development of safer and more effective immunotherapies for patients with solid tumors.”
Jineon So, Head of R&D, Life Sciences Division at LG Chem, commented: “LabGenius possesses a highly capable and systematic platform that enables rapid candidate exploration and early evaluation through a closed-loop structure integrating automated wet labs and computational dry labs. Through this collaboration, we aim to quickly identify novel oncology drug candidates with improved efficacy and reduced toxicity in areas of high unmet medical need.”
Under the terms of the licensing agreement, LabGenius will advance the programme through preclinical research, including in vitro efficacy studies, after which LG Chem will perform further pre-clinical development work, including in vivo studies, and then have the option to in-license the asset. LabGenius will receive an undisclosed upfront payment and potential early milestones, plus, if the option is exercised, potential triple-digit million clinical, regulatory and commercial milestones, along with royalties on net sales. LG Chem will fund all research and development activities conducted under the collaboration.
Contacts
Media: press@labgeni.us
Corporate / business development: partnerships@labgeni.us
Total Page Views: 56
